open access
The management of nivolumab-induced endocrine immune-related adverse events
open access
Abstract
Abstract
Keywords
immunotherapy, nivolumab, hypophysitis, thyroiditis, diabetes mellitus type 1


Title
The management of nivolumab-induced endocrine immune-related adverse events
Journal
Issue
Article type
Review paper
Pages
295-300
Published online
2018-01-04
Page views
640
Article views/downloads
1473
DOI
10.5603/OCP.2017.0035
Bibliographic record
Oncol Clin Pract 2017;13(6):295-300.
Keywords
immunotherapy
nivolumab
hypophysitis
thyroiditis
diabetes mellitus type 1
Authors
Maria Stelmachowska-Banaś
Wojciech Zgliczyński


- Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015; 373(1): 23–34.
- Orlov S, Salari F, Kashat L, et al. Induction of painless thyroiditis in patients receiving programmed death 1 receptor immunotherapy for metastatic malignancies. J Clin Endocrinol Metab. 2015; 100(5): 1738–1741.
- Weber JS, Postow M, Lao CD, et al. Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents. Oncologist. 2016; 21(10): 1230–1240.
- Kottschade L, Brys A, Peikert T, et al. Midwest Melanoma Partnership. A multidisciplinary approach to toxicity management of modern immune checkpoint inhibitors in cancer therapy. Melanoma Res. 2016; 26(5): 469–480.
- Byun DJ, Wolchok JD, Rosenberg LM, et al. Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies. Nat Rev Endocrinol. 2017; 13(4): 195–207.
- OPDIVO®(nivolumab) Prescribing Information. https://packageinserts.bms.com/pi/pi_opdivo.pdf (10/2016).
- Corsello SM, Barnabei A, Marchetti P, et al. Endocrine side effects induced by immune checkpoint inhibitors. J Clin Endocrinol Metab. 2013; 98(4): 1361–1375.
- Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363(8): 711–723.
- Faje A. Immunotherapy and hypophysitis. Pituitary 19 2016: 82–92.
- Torino F, Barnabei A, Paragliola RM, et al. mAbs and pituitary dysfunction: clinical evidence and pathogenic hypotheses. Eur J Endocrinol. 2013; 169: R153–R164.
- Faje AT, Sullivan R, Lawrence D, et al. Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab. 2014; 99(11): 4078–4085.
- Nishimura H, Honjo T. PD-1: an inhibitory immunoreceptor involved in peripheral tolerance. Trends Immunol. 2001; 22(5): 265–268.
- Iwama S, De Remigis A, Callahan MK, et al. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci Transl Med. 2014; 6(230): 230ra45.
- Okano Y, Satoh T, Horiguchi K, et al. Nivolumab-induced hypophysitis in a patient with advanced malignant melanoma. Endocr J. 2016; 63(10): 905–912.
- Yamauchi I, Sakane Y, Fukuda Y, et al. Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study. Thyroid. 2017; 27(7): 894–901.
- Delivanis DA, Gustafson MP, Bornschlegl S, et al. Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms. J Clin Endocrinol Metab. 2017; 102(8): 2770–2780.
- Morganstein DL, Lai Z, Spain L, et al. Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma. Clin Endocrinol (Oxf). 2017; 86(4): 614–620.
- McMillen B, Dhillon MS, Yong-Yow S. A rare case of thyroid storm. BMJ Case Rep. 2016; 2016: 10.1136/bcr–2016.
- Hughes J, Vudattu N, Sznol M, et al. Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy. Diabetes Care. 2015; 38(4): e55–e57.
- Godwin JL, Jaggi S, Sirisena I, et al. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer. J Immunother Cancer. 2017; 5: 40.
- Okamoto M, Okamoto M, Gotoh K, et al. Fulminant type 1 diabetes mellitus with anti-programmed cell death-1 therapy. J Diabetes Investig. 2016; 7(6): 915–918.
- Miyoshi Y, Ogawa O, Oyama Yu. Nivolumab, an Anti-Programmed Cell Death-1 Antibody, Induces Fulminant Type 1 Diabetes. Tohoku J Exp Med. 2016; 239(2): 155–158.
- Lowe JR, Perry DJ, Salama AKS, et al. Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy. J Immunother Cancer. 2016; 4: 89.